Mallinckrodt plc, a global specialty pharmaceutical company, announced that it will report first quarter 2023 earnings results for the period ended March 31, 2023, on Tuesday, May 9, 2023.
Mallinckrodt to Report Earnings Results for First Quarter 2023 Read More »
Eli Lilly and Company and Amphastar Pharmaceuticals, Inc. have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company focused on developing, manufacturing, and marketing injectable, intranasal, and inhalation products including experience with a glucagon product.
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
En este Short averiguaremos qué factores biológicos influyen en el color de los ojos. …
Samsung Biologics, the world’s leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2023.
Samsung Biologics Reports First Quarter 2023 Financial Results Read More »
Everest Medicines announced that Nefecon, the first-in-disease treatment for primary immunoglobulin A nephropathy, has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary.
Zylox-Tonbridge Medical Technology Co., Ltd. announced the signing of a strategic agreement with Guangdong Hicicare Science Co., Ltd. With the collaboration, Zylox-Tonbridge and Hicicare plan to introduce and help accelerate the commercialization of co-branded vascular guidewire products in the neuro- and peripheral-vascular interventional device market segments in a move to provide innovative vascular access solutions
Net sales amounted to SEK 140.6 million, corresponding to an increase of 52 percent in SEK and 39 percent adjusted for currency effects.
XVIVO Presents Interim Report January-March 2023 Read More »
MaaT Pharma reported that the U.S. Food and Drug Administration has lifted the clinical hold and cleared the Investigational New Drug application to initiate in the U.S. an open-label, single arm Phase 3 pivotal clinical trial evaluating the safety and efficacy of MaaT013 to treat gastrointestinal acute Graft-versus-Host Disease as a third line of treatment.
Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3rd ISIET’s International Symposium on Inner Ear Therapeutics, an event sponsored by Sensorion, taking place on April 28-30, 2023, in Marrakech, Morocco.
